304 reports of this reaction
2.1% of all MICONAZOLE NITRATE reports
#8 most reported adverse reaction
VULVOVAGINAL SWELLING is the #8 most commonly reported adverse reaction for MICONAZOLE NITRATE, manufactured by H E B. There are 304 FDA adverse event reports linking MICONAZOLE NITRATE to VULVOVAGINAL SWELLING. This represents approximately 2.1% of all 14,417 adverse event reports for this drug.
Patients taking MICONAZOLE NITRATE who experience vulvovaginal swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VULVOVAGINAL SWELLING is a less commonly reported adverse event for MICONAZOLE NITRATE, but still significant enough to appear in the safety profile.
In addition to vulvovaginal swelling, the following adverse reactions have been reported for MICONAZOLE NITRATE:
The following drugs have also been linked to vulvovaginal swelling in FDA adverse event reports:
VULVOVAGINAL SWELLING has been reported as an adverse event in 304 FDA reports for MICONAZOLE NITRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VULVOVAGINAL SWELLING accounts for approximately 2.1% of all adverse event reports for MICONAZOLE NITRATE, making it a notable side effect.
If you experience vulvovaginal swelling while taking MICONAZOLE NITRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.